Across TCGA pan-cancer cohorts, UGT2A1 mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated UGT2A1 data layer compared with 17 for mass-spec protein and 11 for mutation status.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher UGT2A1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated UGT2A1 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.
LUAD are the cancer types where UGT2A1 mass-spec protein most reproducibly stratifies survival.